Biomarker des Schlaganfalls

Zusammenfassung

In der jüngeren Vergangenheit sind eine ganze Reihe von Serum-Biomarkern zu ihrer Bedeutung bei zerebrovaskulären Erkrankungen untersucht worden. Hierbei stand neben der Diagnose und Differenzierung akuter Schlaganfall-Syndrome auch die individuelle Prognoseabschätzung in verschiedenen klinischen Situationen im Vordergrund. Der Einsatz von S100B und zellulärem Fibronektin (c-FN) zur Vorhersage eines malignen Mediainfarktes erscheint zum jetzigen Zeitpunkt die konkreteste und zuverlässigste Applikation von Serum-Biomarkern zu sein. Darüber hinaus lässt sich aus der Vielzahl der unterschiedlichen Studien zum jetzigen Zeitpunkt noch kein einheitliches Bild bezüglich konkreter Anwendungen im klinischen Alltag ableiten. In der Zukunft werden über die Pilotstudien hinaus ausreichend dimensionierte klinische Studien notwendig sein, um die spezifische Bedeutung von Biomarkern bzw. -kombinationen in klinisch relevanten Fragestellungen eindeutig zu evaluieren. Der vorliegende Artikel gibt eine Übersicht über den aktuellen Stand der klinischen Forschung.

Summary

In the past, a numerous amount of blood serum biomarkers were analysed concerning their significance of relation with cerebrovascular diseases. Alongside the diagnosis and differentiation of an acute stroke-syndrome, the individual future prospects in various clinical situations are in the foreground. The application of S100B and cellular fibronectin seems to be the most reliable and precise application of blood serum biomarker to predict a malignant course of acute middle cerebral artery infarction at the moment. Despite the various amount of clinical trials, there is no concrete prospect of clinical application at this point. Surely the conduction of dimensioned clinical trials concerning these pilot studies will be necessary in order to evaluate the specified meaning of blood serum biomarkers and their combination with clinically relevant questionings. The state of affairs can be gathered from the present article.

Schlüsselwörter

Ischämischer Schlaganfall - hämorrhagischer Schlaganfall - Serummarker - Biomarker - Diagnose - Prognose

Keywords

Ischemic stroke - hemorrhagic stroke - blood serum marker - biomarker - diagnosis - prognosis

• Literatur

• 1 Allard L, Burkhard PR, Lescuyer P, Burgess JA, Walter N, Hochstrasser DF. et al. PARK7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke. Clin Chem 2005; 51: 2043-2051.
• 2 Allard L, Lescuyer P, Burgess J, Leung KY, Ward M, Walter N. et al. ApoC-I and ApoC-III as potential plasmatic markers to distinguish between ischemic and hemorrhagic stroke. Proteomics 2004; 04: 2242-2251.
• 3 Castellanos M, Leira R, Serena J, Blanco M, Pedraza S, Castillo J. et al. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 2004; 35: 1671-1676.
• 4 Dambinova SA, Khounteev GA, Izykenova GA, Zavolokov IG, Ilyukhina AY, Skoromets AA. Blood test detecting autoantibodies to N-methyl-D-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin Chem 2003; 49: 1752-1762.
• 5 Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M. et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002; 08: 495-505.
• 6 Foerch C, Curdt I, Yan B, Dvorak F, Hermans M, Berkefeld J. et al. Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke. J Neurol Neurosurg Psychiatry 2006; 77: 181-187.
• 7 Foerch C, du Mesnil de Rochemont R, Singer O, Neumann-Haefelin T, Buchkremer M, Zanella FE. et al. S100B as a surrogate marker for successful clot lysis in hyperacute middle cerebral artery occlusion. J Neurol Neurosurg Psychiatry 2003; 74: 322-325.
• 8 Foerch C, Otto B, Singer OC, Neumann-Haefelin T, Yan B, Berkefeld J. et al. Serum S100B predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion. Stroke 2004; 35: 2160-2164.
• 9 Foerch C, Singer OC, Neumann-Haefelin T, du Mesnil de Rochemont R, Steinmetz H, Sitzer M. Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction. Arch Neurol 2005; 62: 1130-1134.
• 10 Heo JH, Kim SH, Lee KY, Kim EH, Chu CK, Nam JM. Increase in plasma matrix metalloproteinase-9 in acute stroke patients with thrombolysis failure. Stroke 2003; 34: e48-50.
• 11 Jauch EC, Lindsell C, Broderick J, Fagan SC, Tilley BC, Levine SR. Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study. Stroke 2006; 37: 2508-2513.
• 12 Lynch JR, Blessing R, White WD, Grocott HP, Newman MF, Laskowitz DT. Novel diagnostic test for acute stroke. Stroke 2004; 35: 57-63.
• 13 Marti-Fabregas J, Borrell M, Cocho D, Belvis R, Castellanos M, Montaner J. et al. Hemostatic markers of recanalization in patients with ischemic stroke treated with rt-PA. Neurology 2005; 65: 366-370.
• 14 Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M. et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003; 107: 598-603.
• 15 Ribo M, Montaner J, Molina CA, Arenillas JF, Santamarina E, Alvarez-Sabin J. Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator. Thromb Haemost 2004; 91: 1146-1151.
• 16 Serena J, Blanco M, Castellanos M, Silva Y, Vivancos J, Moro MA. et al. The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. Stroke 2005; 36: 1921-1926.
• 17 Wunderlich MT, Wallesch CW, Goertler M. Release of glial fibrillary acidic protein is related to the neurovascular status in acute ischemic stroke. Eur J Neurol 2006; 13: 1118-1123.